FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Articles|October 20, 2020
Video: Myopia control data and what’s to come with Dr. Noel Brennan
What the data shows on myopia management
Advertisement
Johnson & Johnson Vision’s research fellow Noel Brennan, BOptom, MScOptom, PhD, FAAO, talks with Optometry Times® Editor in Chief Gretchyn M. Bailey, NCLC, FAAO, about myopia control and what the data is showing. In addition, Dr. Brennan explains his role as a research fellow. He also offers takeaways to clinicians interested in offering myopia control to their pediatric patients. Take a look!
Advertisement
Related to this article
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5